Skip To The Main Content

FDA's ORA Realignment, MRA, NIPP, Concept of Operations: How it All Fits Together

November December 2018

Just over a year ago, the U.S. FDA released detailed information about the restructuring of the newly realigned Office of Regulatory Affairs (ORA) (1). Alonza Cruse, Director, Office of Pharmaceutical Quality Operations, ORA, provided an update on this and other ORA initiatives on Sept. 24 in the second plenary of the 2018 PDA/FDA Joint Regulatory Conference.

You need to Login to view the full article. Please Login. Not a Member? Join today!

PDA Members Save Substantially